WO1995004551A1 - Preparation absorbable par voie percutanee - Google Patents
Preparation absorbable par voie percutanee Download PDFInfo
- Publication number
- WO1995004551A1 WO1995004551A1 PCT/JP1994/001282 JP9401282W WO9504551A1 WO 1995004551 A1 WO1995004551 A1 WO 1995004551A1 JP 9401282 W JP9401282 W JP 9401282W WO 9504551 A1 WO9504551 A1 WO 9504551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- preparation
- fatty acid
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- the present invention relates to a transdermal absorption preparation containing a drug, and monoglyceride and a fatty acid as a transdermal absorption enhancer.
- the present invention relates to a percutaneous absorption preparation containing a monodaliceride and a fatty acid mixed with a drug for the purpose of enhancing skin permeability of a drug that is hardly soluble in water.
- Solubilizing agents such as polyethylene glycol 400 and propylene glycol have been used to increase the transdermal absorption of poorly water-soluble drugs.
- medium-chain fatty acid glycerin monoester has a transdermal absorption promoting effect.
- Japanese Unexamined Patent Publication (Kokai) No. 63-227520 uses monolaurin, which is a glycerin monoester of laurate, as a skin permeation enhancer.
- drugs that are extremely poorly soluble in water generally have a problem that they are not sufficiently percutaneously absorbed even when these solubilizers or skin permeation enhancers such as medium-chain fatty acid glycerin monoester are used.
- the inventors of the present invention have conducted intensive studies to solve this problem, and surprisingly found that the coexistence of fatty acids with monoglyceride significantly enhanced skin permeability, and completed the present invention. did.
- the transdermal absorption preparation of the present invention is characterized by containing a drug, and monoglyceride and a fatty acid as a transdermal absorption enhancer.
- Suitable monodalicerides used in this formulation include those in the pharmaceutical formulation field. And mono-purine, mono-perin, mono-myristin, mono-no, remitin, mono-stearin, mono-olein and other medium- or long-chain saturated or unsaturated fatty acid glycerin monoesters. They can be used alone or in mixtures. More preferred are saturated or unsaturated fatty acid dalycerin monoesters having 10 to 20 carbon atoms, and most preferred are mono-purine, monolaurin and monoolein. Suitable fatty acids for use in this formulation include those commonly used in the field of pharmaceutical formulation, for example, capric acid, lauric acid, myristic acid, c. Single- or medium-chain or long-chain saturated or unsaturated fatty acids such as lumitic acid and stearic acid, or mixtures thereof. More preferred are C 12 -C 18 saturated fatty acids, and most preferred is stearic acid.
- the preparation of the present invention can further contain, if necessary, general-purpose additives usually used in the process of preparation of a preparation, such as excipients, coloring agents, and solubilizing agents.
- examples of the solubilizer include polyhydric alcohols such as propylene glycol, polyethylene glycol and glycerin as hydrophilic solvents, monohydric alcohols such as ethyl alcohol and isopropyl alcohol, and mixtures thereof. Furthermore, long-chain or cyclic esters such as isopropyl myristate, getyl sebacate, diisopropyl adipate, and propylene carbonate can be mentioned.
- Ointment bases include, for example, vegetable or animal waxes (eg, beeswax, carnauba wax, beeswax, etc.), paraffins (eg, paraffin, liquid paraffin, etc.), petrolatums (eg, white petrolatum, etc.) Is mentioned. These may be used as a mixture.
- vegetable or animal waxes eg, beeswax, carnauba wax, beeswax, etc.
- paraffins eg, paraffin, liquid paraffin, etc.
- petrolatums eg, white petrolatum, etc.
- ordinary creams, gels, or cataplasms It can also be a lotion preparation.
- the ratio of the skin permeation enhancer in the present preparation is 1 to 50% by weight, preferably 5 to 20% by weight.
- the preparation of the present invention can be produced usually by dissolving a drug with a solubilizing agent such as propylene dalicol, adding monoglyceride and a fatty acid, and, if necessary, mixing with a conventional additive.
- a solubilizing agent such as propylene dalicol
- the drug used in the present invention is not particularly limited and includes various drugs.
- drugs for treating infectious diseases such as antibiotics and antiviral drugs, antiasthmatic drugs, analgesics, anti-inflammatory drugs, anti-inflammatory drugs, Drugs such as angina pectoris and antipsychotics.
- drugs for treating infectious diseases such as antibiotics and antiviral drugs, antiasthmatic drugs, analgesics, anti-inflammatory drugs, anti-inflammatory drugs, Drugs such as angina pectoris and antipsychotics.
- drugs particularly preferred are those that have pharmacological activities such as tachykinin antagonism, especially substance P antagonism, neurokinin A antagonism, and neurokinin B antagonism, and are useful for the treatment or prevention of pain and the like.
- Useful compounds described in JP-A-4-120996 are useful for the treatment or prevention of pain and the like.
- Compound (A) (1 part by weight) is added to propylene glycol (5 parts by weight), and heated to 75 to dissolve. Monolaurin (10 parts by weight), stearic acid (1 part by weight), beeswax (3 parts by weight), liquid paraffin (40 parts by weight) and white petrolatum (40 parts by weight) were added to a propylene glycol solution of compound (1). ) And dissolve by heating at 75 ° C.
- the above-mentioned melt is put into an aziomomixer set to a temperature of 75 ⁇ 2 ° C in the kettle and stirred (homomixer: 500 rpm, paddle mixer: 30 rpm, stirring time: 10 minutes). Next, homo mixer 3 000 rpm, middle mixer 3
- Example 2 An ointment having the following composition is prepared in the same manner as in Example 1.
- the skin permeability of the drug could be increased.
- the results of a transdermal absorption test will be described to show the effects obtained by the transdermal absorption preparation of the present invention.
- Rats SD, 7 to 8 weeks old, average body weight: about 250 g
- the abdomen was shaved, and 24 hours later, 100 mg of the test preparation was applied to the skin of the abdomen 10 cm 2 .
- Blood was collected over time from the clavicle vein, and plasma was obtained after centrifugation, and the plasma concentration was measured by high performance liquid chromatography.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94923065A EP0719561A4 (en) | 1993-08-10 | 1994-08-04 | Percutaneous absorbent preparation |
US08/592,307 US5747069A (en) | 1993-08-10 | 1994-08-04 | Percutaneously absorbable preparation |
KR1019960700603A KR960703621A (ko) | 1993-08-10 | 1994-08-04 | 경피흡수 제제(Percutaneously absorbable preparation) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5/198014 | 1993-08-10 | ||
JP19801493 | 1993-08-10 | ||
JP31631993 | 1993-12-16 | ||
JP5/316319 | 1993-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995004551A1 true WO1995004551A1 (fr) | 1995-02-16 |
Family
ID=26510724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001282 WO1995004551A1 (fr) | 1993-08-10 | 1994-08-04 | Preparation absorbable par voie percutanee |
Country Status (6)
Country | Link |
---|---|
US (1) | US5747069A (ja) |
EP (1) | EP0719561A4 (ja) |
KR (1) | KR960703621A (ja) |
CN (1) | CN1128955A (ja) |
CA (1) | CA2169172A1 (ja) |
WO (1) | WO1995004551A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033722A1 (fr) * | 1995-04-27 | 1996-10-31 | Kanebo, Ltd. | Preparation externe contenant de l'emedastine |
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
GB2327611A (en) * | 1994-10-26 | 1999-02-03 | Novartis Ag | Stabilisation of Macrolide Compositions |
JP2002522488A (ja) * | 1998-08-12 | 2002-07-23 | エドコ・トレイディング・アンド・レプレゼンテーション・カンパニー・リミテッド | ニメスリドを含む局所用医薬組成物 |
JP2012229245A (ja) * | 2002-05-28 | 2012-11-22 | Nycomed Gmbh | 局所適用可能な薬剤学的製剤 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
MXPA06002719A (es) * | 2003-09-09 | 2006-09-04 | 3M Innovative Properties Co | Composiciones antimicrobianas y metodos. |
EP1672989B1 (en) * | 2003-09-09 | 2012-04-25 | 3M Innovative Properties Company | Concentrated antimicrobial compositions and methods |
US7105263B2 (en) * | 2003-12-30 | 2006-09-12 | Samsung Electronics Company | Dry toner comprising encapsulated pigment, methods and uses |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
CN101137359B (zh) * | 2005-03-10 | 2011-01-12 | 3M创新有限公司 | 治疗耳感染的方法 |
EP1868686A2 (en) * | 2005-03-10 | 2007-12-26 | 3M Innovative Properties Company | Antimicrobial pet wipes |
EP2497459B1 (en) * | 2005-03-10 | 2019-04-24 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
CN101137357B (zh) * | 2005-03-10 | 2012-07-04 | 3M创新有限公司 | 含有羟基羧酸的酯的抗微生物组合物 |
US20080075793A1 (en) * | 2006-09-21 | 2008-03-27 | Dunshee Wayne K | Antiviral compositions and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035418A (ja) * | 1989-05-31 | 1991-01-11 | Kowa Co | 鎮咳去痰ソフトカプセル剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4400295A (en) * | 1979-03-24 | 1983-08-23 | Loire Cosmetics Co., Ltd. | Emulsifier composition |
US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
IL92537A (en) * | 1988-12-15 | 1994-04-12 | Riker Laboratories Inc | Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine |
GB8929070D0 (en) * | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
-
1994
- 1994-08-04 EP EP94923065A patent/EP0719561A4/en not_active Withdrawn
- 1994-08-04 CA CA002169172A patent/CA2169172A1/en not_active Abandoned
- 1994-08-04 WO PCT/JP1994/001282 patent/WO1995004551A1/ja not_active Application Discontinuation
- 1994-08-04 US US08/592,307 patent/US5747069A/en not_active Expired - Fee Related
- 1994-08-04 CN CN94193053A patent/CN1128955A/zh active Pending
- 1994-08-04 KR KR1019960700603A patent/KR960703621A/ko not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035418A (ja) * | 1989-05-31 | 1991-01-11 | Kowa Co | 鎮咳去痰ソフトカプセル剤 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2327611A (en) * | 1994-10-26 | 1999-02-03 | Novartis Ag | Stabilisation of Macrolide Compositions |
GB2327611B (en) * | 1994-10-26 | 1999-06-02 | Novartis Ag | Macrolide compositions |
WO1996033722A1 (fr) * | 1995-04-27 | 1996-10-31 | Kanebo, Ltd. | Preparation externe contenant de l'emedastine |
WO1998041191A1 (fr) * | 1997-03-14 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preparation pour aerosol |
US6284226B1 (en) * | 1997-03-14 | 2001-09-04 | Fujisawa Pharmaceutical Co., Ltd. | Aerosol composition containing middle-chain fatty acid triglyceride dispersant |
JP2002522488A (ja) * | 1998-08-12 | 2002-07-23 | エドコ・トレイディング・アンド・レプレゼンテーション・カンパニー・リミテッド | ニメスリドを含む局所用医薬組成物 |
JP4653308B2 (ja) * | 1998-08-12 | 2011-03-16 | エドコ・パザルラマ・タニティム・ティカレット・リミテッド・シルケティ | ニメスリドを含む局所用医薬組成物 |
JP2012229245A (ja) * | 2002-05-28 | 2012-11-22 | Nycomed Gmbh | 局所適用可能な薬剤学的製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0719561A1 (en) | 1996-07-03 |
US5747069A (en) | 1998-05-05 |
EP0719561A4 (en) | 1997-07-30 |
CA2169172A1 (en) | 1995-02-16 |
CN1128955A (zh) | 1996-08-14 |
KR960703621A (ko) | 1996-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995004551A1 (fr) | Preparation absorbable par voie percutanee | |
CA2002300C (en) | Compositions for the transdermal delivery of pharmaceutical actives | |
US5041437A (en) | Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt | |
JP2002513748A (ja) | ゲル化性薬剤組成物 | |
EP0159167A2 (en) | Ointment base | |
CA2000837A1 (en) | Gel bases for pharmaceutical compositions | |
HU191659B (en) | Process for producing percutane pharmaceutical compositions | |
JPH02191215A (ja) | ブプレノルフイン塩類の経皮デリバリー用組成物 | |
JP3487633B2 (ja) | 皮膚疾患治療乳剤 | |
JP2855135B2 (ja) | サイクロスポリン含有軟質カプセル剤組成物 | |
WO2011070318A2 (en) | Topical formulation | |
WO2004006960A1 (ja) | 経皮吸収製剤 | |
JP3056694B2 (ja) | 新規な治療用抗炎症鎮痛医薬組成物およびその製造法 | |
JPH05178763A (ja) | 難溶解性薬物溶解剤組成物 | |
JPH0134968B2 (ja) | ||
JPH0840880A (ja) | 軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法 | |
JPH0676328B2 (ja) | ステロイドクリ−ム製剤 | |
JPS6218526B2 (ja) | ||
WO2008078905A1 (en) | Compositions for external use containing minoxidil for hair growth which have an improved skin permeability | |
JPH0135807B2 (ja) | ||
JPS59216818A (ja) | 経皮吸収外用製剤 | |
JP2838297B2 (ja) | コルヒチン含有外用剤 | |
EP2340016A2 (en) | Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate | |
JP4235264B2 (ja) | メシル酸プリジノール含有外用剤 | |
JPS62215528A (ja) | 経皮投与製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94193053.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994923065 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2169172 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08592307 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994923065 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994923065 Country of ref document: EP |